Journey Medical Corp (DERM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Journey Medical Corp (DERM) has a cash flow conversion efficiency ratio of -0.200x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.36 Million) by net assets ($31.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DERM net asset quality score to measure how much of total assets are equity-financed.
Journey Medical Corp - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Journey Medical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Journey Medical Corp to evaluate the quality of earnings relative to operating cash generation.
Journey Medical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Journey Medical Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Paik Kwang Ind
KO:001340
|
0.021x |
|
Green Cross Lab Cell Corporation
KQ:144510
|
0.015x |
|
China Automotive Systems Inc
NASDAQ:CAAS
|
0.069x |
|
Sang-A Frontec Co.Ltd
KQ:089980
|
0.031x |
|
Globe Union Industrial Corp
TW:9934
|
0.044x |
|
Red Planet Indonesia Tbk
JK:PSKT
|
0.006x |
|
Panatlântica S.A
SA:PATI3
|
0.069x |
|
Samindo Resources Tbk
JK:MYOH
|
0.064x |
Annual Cash Flow Conversion Efficiency for Journey Medical Corp (2014–2025)
The table below shows the annual cash flow conversion efficiency of Journey Medical Corp from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see DERM stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $31.85 Million | $-12.44 Million | -0.391x | +14.12% |
| 2024-12-31 | $20.07 Million | $-9.13 Million | -0.455x | -276.62% |
| 2023-12-31 | $20.35 Million | $5.24 Million | 0.257x | +132.31% |
| 2022-12-31 | $16.98 Million | $-13.53 Million | -0.797x | -1436.30% |
| 2021-12-31 | $42.04 Million | $-2.18 Million | -0.052x | -110.40% |
| 2020-12-31 | $10.29 Million | $5.13 Million | 0.499x | -84.78% |
| 2019-12-31 | $2.75 Million | $9.02 Million | 3.277x | -86.10% |
| 2018-12-31 | $-9.04 Million | $-213.10 Million | 23.575x | +3493.55% |
| 2017-12-31 | $149.65 Million | $-103.96 Million | -0.695x | -131.88% |
| 2016-12-31 | $247.37 Million | $-74.11 Million | -0.300x | -14.71% |
| 2015-12-31 | $185.47 Million | $-48.44 Million | -0.261x | -27.73% |
| 2014-12-31 | $153.58 Million | $-31.40 Million | -0.204x | -- |
About Journey Medical Corp
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat sev… Read more